LBF20407HO04: Difference between revisions
No edit summary |
No edit summary |
||
| (2 intermediate revisions by the same user not shown) | |||
| Line 6: | Line 6: | ||
|LipidBank=DFA8105 | |LipidBank=DFA8105 | ||
|LipidMaps=LMFA03060050 | |LipidMaps=LMFA03060050 | ||
|SysName=(8S,15S) -Dihydroxy- (5-cis, | |SysName=(8S,15S) -Dihydroxy- (cis-5,trans-9,cis-11,trans-13) -eicosatetraenoic acid | ||
|Common Name=&&(8S,15S) -Dihydroxy- (5Z,9E,11Z,13E) -eicosatetraenoic acid&& | |Common Name=&&(8S,15S) -Dihydroxy- (5Z,9E,11Z,13E) -eicosatetraenoic acid&&8,15-DiHETE&& | ||
|UV Spectra= lambda max: 269 nm epsilon : 40,000 | |UV Spectra= lambda max: 269 nm epsilon : 40,000 | ||
|Source=8(S),15(S)-DiHETE is formed when15(S)-HETE is subjected to further oxidation by 15-lipoxygenase [[Reference:Morita_E:Schroder_JM:Christophers_E:,J. Immunol.,1990,144,1893|{{RelationTable/GetFirstAuthor|Reference:Morita_E:Schroder_JM:Christophers_E:,J. Immunol.,1990,144,1893}}]]. | |Source=8(S),15(S)-DiHETE is formed when15(S)-HETE is subjected to further oxidation by 15-lipoxygenase [[Reference:Morita_E:Schroder_JM:Christophers_E:,J. Immunol.,1990,144,1893|{{RelationTable/GetFirstAuthor|Reference:Morita_E:Schroder_JM:Christophers_E:,J. Immunol.,1990,144,1893}}]]. | ||
| Line 14: | Line 14: | ||
|Symbol=8(S),15(S)-DiHETE | |Symbol=8(S),15(S)-DiHETE | ||
|Biological Activity=8(S),15(S)-diHETE causes chemotaxis of human eosinophils with an ED _{50} of 1.5 μ M but is not chemotactic for neutrophils [[Reference:Morita_E:Schroder_JM:Christophers_E:,J. Immunol.,1990,144,1893|{{RelationTable/GetFirstAuthor|Reference:Morita_E:Schroder_JM:Christophers_E:,J. Immunol.,1990,144,1893}}]]. 8(S),15(S)-diHETE exhibits hypoalgesic activity by antagonizing the hyperalgesic activity of 8(R),15(S)-diHETE and LTB 4 when measuring nociceptive activity in the rat hindpaw model of pain [[Reference:Oliw_EH:,Biochim. Biophys. Acta,1984,795,384|{{RelationTable/GetFirstAuthor|Reference:Oliw_EH:,Biochim. Biophys. Acta,1984,795,384}}]]. | |Biological Activity=8(S),15(S)-diHETE causes chemotaxis of human eosinophils with an ED _{50} of 1.5 μ M but is not chemotactic for neutrophils [[Reference:Morita_E:Schroder_JM:Christophers_E:,J. Immunol.,1990,144,1893|{{RelationTable/GetFirstAuthor|Reference:Morita_E:Schroder_JM:Christophers_E:,J. Immunol.,1990,144,1893}}]]. 8(S),15(S)-diHETE exhibits hypoalgesic activity by antagonizing the hyperalgesic activity of 8(R),15(S)-diHETE and LTB 4 when measuring nociceptive activity in the rat hindpaw model of pain [[Reference:Oliw_EH:,Biochim. Biophys. Acta,1984,795,384|{{RelationTable/GetFirstAuthor|Reference:Oliw_EH:,Biochim. Biophys. Acta,1984,795,384}}]]. | ||
}} | |||
{{MassbankSpectra| | |||
UT000199 | |||
UT000200 | |||
UT000201 | |||
UT000202 | |||
UT000203 | |||
UT000204 | |||
UT000205 | |||
UT000206 | |||
UT000207 | |||
}} | }} | ||
{{Lipid/Footer}} | {{Lipid/Footer}} | ||
Latest revision as of 00:00, 17 January 2014
| LipidBank Top (トップ) |
Fatty acid (脂肪酸) |
Glycerolipid (グリセロ脂質) |
Sphingolipid (スフィンゴ脂質) |
Journals (雑誌一覧) |
How to edit (ページの書き方) |
| IDs and Links | |
|---|---|
| LipidBank | DFA8105 |
| LipidMaps | LMFA03060050 |
| CAS | |
| KEGG | {{{KEGG}}} |
| KNApSAcK | {{{KNApSAcK}}} |
| mol | LBF20407HO04 |
| (8S,15S) -Dihydroxy- (5Z,9E,11Z,13E) -eicosatetraenoic acid | |
|---|---|
| |
| Structural Information | |
| (8S,15S) -Dihydroxy- (cis-5,trans-9,cis-11,trans-13) -eicosatetraenoic acid | |
| |
| 8(S),15(S)-DiHETE | |
| Formula | C20H32O4 |
| Exact Mass | 336.23005951199997 |
| Average Mass | 336.46567999999996 |
| SMILES | C(CCC(C=CC=CC=CC(CC=CCCCC(O)=O)O)O)CC |
| Physicochemical Information | |
| 8(S),15(S)-DiHETE is formed when15(S)-HETE is subjected to further oxidation by 15-lipoxygenase Morita_E et al.. | |
| 8(S),15(S)-diHETE causes chemotaxis of human eosinophils with an ED _{50} of 1.5 μ M but is not chemotactic for neutrophils Morita_E et al.. 8(S),15(S)-diHETE exhibits hypoalgesic activity by antagonizing the hyperalgesic activity of 8(R),15(S)-diHETE and LTB 4 when measuring nociceptive activity in the rat hindpaw model of pain Oliw_EH . | |
| Spectral Information | |
| Mass Spectra | |
| UV Spectra | λ max: 269 nm ε : 40,000 |
| IR Spectra | |
| NMR Spectra | |
| Other Spectra | |
| Chromatograms | |
| Reported Metabolites, References | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
